Tesamorelin โ FDA-Approved GHRH Analogue for Lipodystrophy. Physician-Supervised
Tesamorelin is an FDA-approved, stabilised GHRH analogue with a well-established clinical track record. It holds approval for HIV-related lipodystrophy โ a condition involving abnormal visceral fat accumulation โ and is being investigated in other metabolic contexts including age-related visceral adiposity. It is available at OptiMale USA following thorough clinical assessment.
WHAT IS IT?
Understanding Tesamorelin
esamorelin is a modified form of GHRH that includes a trans-3-hexenoic acid group attached to the N-terminus, which stabilises the molecule against enzymatic degradation and extends its activity compared to native GHRH. It activates GHRH receptors in the pituitary, stimulating GH release in a physiological, pulsatile pattern โ the same mechanism used by sermorelin and CJC-1295, but with FDA-approved clinical backing for a specific indication.
Its FDA approval for HIV-related lipodystrophy โ where antiretroviral therapy causes characteristic visceral fat accumulation โ is based on strong randomised clinical trial data showing significant reduction in trunk fat. This clinical evidence base distinguishes tesamorelin from most other GH peptides, which do not have equivalent approved indications. Research is also examining tesamorelin’s potential in age-related visceral adiposity and metabolic health beyond the HIV context. At OptiMale USA, tesamorelin is discussed in the context of your full metabolic and body composition assessment.
Quick Facts
Injection
Timeline: Measurable visceral fat reduction at 8-12 weeks; optimal results at 26 weeks
Lab required: Yes
Ongoing maintenance: Yes; continued therapy recommended for sustained visceral fat reduction
Pricing:ย Contact for Pricing
Related Treatments
Benefits
FDA-approved with randomised clinical trial evidence
Tesamorelin's approval for lipodystrophy is backed by multiple randomised controlled trials showing significant trunk fat reduction. This clinical evidence base is stronger than most peptides in the GH category and informs how providers discuss its use in appropriate metabolic contexts.
Visceral fat research
Research has specifically examined tesamorelin's effects on visceral fat โ the metabolically active fat that accumulates around abdominal organs. This distinct focus on trunk fat reduction, documented in clinical trials, is what differentiates tesamorelin's research profile from general GH secretagogues.
Physiological GH release maintained
Like other GHRH analogues, tesamorelin stimulates pituitary GH release in a pulsatile pattern rather than producing constant GH elevation. This physiological approach maintains the body's natural feedback mechanisms.
Body composition research beyond lipodystrophy
Researchers have investigated tesamorelin's effects on body composition markers in populations beyond its approved indication, including men with age-related visceral fat accumulation and declining GH. These are areas of ongoing investigation.
Who Is This For?
Am I a Good Candidate?
Ideal For
- Men with documented visceral fat accumulation and low or declining GH levels confirmed through bloodwork
- Men with metabolic syndrome or elevated trunk fat who have been assessed at OptiMale USA
- Men on antiretroviral therapy experiencing lipodystrophy changes in body fat distribution
- Men whose provider has assessed them as appropriate for a GHRH analogue with specific visceral fat research focus
Not Recommended If
- Men with active malignancy
- Men with pituitary tumours or significantly elevated baseline IGF-1
- Men with hypothyroidism not under active treatment โ GH increase can unmask thyroid deficiency
- Men under 25 or with open growth plates
Safety
Potential Side Effects
Tesamorelin has a well-characterised safety profile from its clinical trial programme. Side effects are generally mild and similar to other GHRH analogues. IGF-1 monitoring is standard throughout all protocols.
- IGF-1 levels โ assessed before starting and regularly throughout the protocol
- Blood glucose โ GH elevation can influence insulin sensitivity, tracked at follow-up
- Thyroid function โ assessed at baseline as GH can unmask subclinical hypothyroidism
- Water retention and joint discomfort โ associated with GH elevation, managed with dose adjustment
- Injection site reactions โ local redness or discomfort, typically transient
- Paraesthesia (tingling) โ reported in some clinical trial participants, usually mild
Common Questions
Frequently Asked Questions
Why does tesamorelin have FDA approval when other GH peptides do not?
Tesamorelin went through the full FDA drug approval process, including large randomised controlled trials specifically examining its effects in HIV-related lipodystrophy. Most other GH peptides have not been taken through this process, meaning they lack equivalent approved indications regardless of their research profile. This regulatory history is one reason tesamorelin is discussed differently to other GHRH analogues at OptiMale USA.
Can tesamorelin be used for visceral fat if I don't have HIV?
Research is examining tesamorelin in populations beyond its approved indication, including men with age-related visceral fat and declining GH levels. This is an off-label use and is discussed with your provider in the context of your individual clinical situation and the current evidence base. All prescribing at OptiMale USA is individualised following thorough assessment.
Can tesamorelin be combined with GHRPs like ipamorelin?
As a GHRH analogue, tesamorelin activates GHRH receptors โ a complementary pathway to GHRP compounds which activate GHSR. Combining both has been investigated in the broader GHRH + GHRP research context. Whether this is appropriate for your protocol is determined during your consultation.
Get started
Discuss Tesamorelin With a Provider
Your free consultation is the first step. A licensed OptiMale USA provider will review your bloodwork, health history, and goals before making any recommendations.